Biotechnology company U.S. Stem Cell, Inc. (USRM) is focused on bringing to market autologous cellular therapies to treat heart damage, and vascular and autoimmune diseases. Its business is focused on developing cell therapy products, along with the sale of test kits and equipment, training services, laboratory services, and cell banking. The company’s strategy is to expand revenue from enterprises such as training services and animal health products and reinvest these profits into the development of its clinical pipeline. Let’s take a look at the financial performance of the company and what’s changed in its key risk factors that investors should know. On the back of higher product sales, U.S.
https://www.tipranks.com/news/what-do-u-s-stem-cells-risk-factors-tell-investors?utm_source=advfn.com&utm_medium=referral